A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab - first results of the PERMAD trial
Antiangiogenic agents are frequently used in the systemic treatment of metastatic colorectal cancer (mCRC). Since these strategies target not the tumor but the tumor associated endothelium establishing positive or negative predictive biomarkers is challenging. Recent research indicated a potentially predictive value of cytokines and angiogenic factors (CAF) for early detection of progression during treatment with chemotherapy and bevacizumab.
The PERMAD trial is a two-phase trial with the primary objective to evaluate of the impact of a personalized, marker-driven treatment approach with early detection of progression and modification of treatment.
Descargar estudio Permad